Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 20/20 | 0.39 |
| ▸ | VEGFA | P15692 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ARNT | P27540 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19872283 | 0.76 | EPAS1 (0.64) | EPAS1VEGFA | |
| SCHEMBL20182727 | 0.75 | EPAS1 (0.65) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19872298 | 0.75 | EPAS1 (0.65) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL29780225 | 0.74 | EPAS1 (0.39) | EPAS1VEGFA | |
| SCHEMBL23461012 | 0.74 | EPAS1 (0.39) | EPAS1VEGFA | |
| SCHEMBL23461066 | 0.74 | EPAS1 (0.41) | EPAS1VEGFA | |
| SCHEMBL29780239 | 0.74 | EPAS1 (0.41) | EPAS1VEGFA | |
| SCHEMBL19865219 | 0.70 | EPAS1 (0.44) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL19865218 | 0.70 | EPAS1 (0.38) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL24910451 | 0.70 | EPAS1 (0.37) | EPAS1VEGFACYP2C9ARNTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | EPAS1 9/4885VEGFA 996/4885CYP2C9 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.